Media Thread, page-9465

Lots of discussion about the prospects of IMU once it delivers good data and positive results.

We should not be deterred by IMU being an Australian company. Here is another Australian company that is taking on BP with a superior product. Interestingly, its SP tripled on the announcement. This is in a different fiel than IMU but the story could be very similar. Not trying to cross promote and I don't own any shares in this company.

Great data can change a company's market exposure - something to remember when we despair IMU's current SP.

ASX-listed Zelira is going head-to-head with Big Pharma. We spoke to its CEO about its place in a US$62 billion market - *

ASX-listed Zelira is going head-to-head with BigPharma. We spoke to its CEO about its place in a US$62 billion market

Health & Biotech

• Zelira announced that its diabetic nerve pain drug outperforms Pfizer’s Lyrica
• Diabetes is a huge market, estimated at a massive US$62 billion in 2022
• * reached out to Zelira’s CEO, Dr. Oludare Odumosu

Diabetesis one of the leading causes of deaths in the world, ranking number 9 on theWorld Health Organisations’s list.

Accordingto data from Precedence Research, the global diabetes drug market size wasestimated at a massive US$62 billion in 2022, and is projected to double by2032.

Untiltoday, scientists have not yet found a cure for the disease, but what they doknow is that high blood sugar causes nerve damage, resulting in mild numbnessin the legs and sometimes pain that can be quite disabling.

As many as50% of people with diabetes suffer from nerve pain, and half of all amputationsannually are associated with the disease.

For years,the current standard drug on the market to deal with the pain has been Pfizer’spregabalin, sold under the brand name Lyrica. This drug generates around US$5 billion a year in annual sales.

But lastmonth, the medical world was rocked when ASX-listed Zelira Therapeutics (ASX:ZLD) said it had come up with an alternative drug that could perform better than Lyrica.

The ZLDshare price tripled when the company announced that top-line results for itsproprietary ZLT-L-007 drug had achieved better reduction in NRSpain scores than Lyrica.

The studyshowed that ZLT-L-007, a cannabinoid-based oral capsule, was safe andwell-tolerated, meeting the primary endpoint for safety with no Serious AdverseEvents (SAE).

The studyalso met its secondary endpoints, including significant decreases in VisualAnalog Scale (VAS) and Short-form McGill scores, among others.